American Society of Hirudotherapy

Hirudin ameliorates kidney injury in DKD mice by decreasing SOD2 β-hydroxybutyrylation mediated ROS level and NLRP3 inflammasome formation

Mechanism study published in FASEB Journal (2026)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: In vitro / laboratorySalivary PharmacologyDrug DevelopmentLi Y et al. · FASEB journal, 2026

Abstract

Inflammation and oxidative stress play crucial roles in the pathogenesis of diabetic kidney disease (DKD). Hirudin, a small molecular polypeptide derived from the salivary glands of leeches, is widely utilized in anti-coagulation and antithrombotic therapies. However, the effects and underlying molecular mechanisms of hirudin on DKD remain unclear. Db/db mice were employed to evaluate the effects of hirudin on DKD. Key parameters assessed included urinary albumin, oral glucose tolerance, glomerular diameter, and the expression levels of NLRP3, IL-1β, IL-18, caspase-1, and reactive oxygen species (ROS). Additionally, proteomic analysis was performed to measure the β-hydroxybutyrylation level of SOD2, and the effects of changes in SOD2 β-hydroxybutyrylation were evaluated by immunoprecipitation. In vivo experiments demonstrated that hirudin significantly improved urinary albumin levels, oral glucose tolerance, and glomerular diameter in diabetic mice. Furthermore, the β-hydroxybutyrylation level of SOD2 was reduced, leading to decreased production of ROS and suppression of NLRP3 inflammasome activation. In vitro experiments indicated that hirudin reduced the polarization of RAW264.7 cells, lowered their ROS levels, diminished NLRP3 inflammasome activation, and reduced the β-hydroxybutyrylation modification level of SOD2. Hirudin can alleviate the progression of DKD by reducing the β-hydroxybutyrylation level of SOD2, which in turn reduces ROS production and NLRP3 inflammasome activation, thereby suppressing inflammation. These findings provide new insights into the potential application of hirudin in the context of DKD.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsNLR Family, Pyrin Domain-Containing 3 ProteinMiceReactive Oxygen SpeciesSuperoxide DismutaseHirudinsDiabetic NephropathiesMaleSuperoxide Dismutase 2InflammasomesMice, Inbred C57BLRAW 264.7 CellsOxidative StressKidneyDiabetes Mellitus, Experimental

Summary

In diabetic db/db mice, hirudin improved urinary albumin, glucose tolerance and glomerular diameter by reducing SOD2 β-hydroxybutyrylation, ROS and NLRP3 inflammasome activation; in RAW264.7 cells, it likewise reduced polarization, ROS, NLRP3 activation and SOD2 β-hydroxybutyrylation.

Why This Matters for Hirudotherapy

This study investigated the molecular mechanisms by which hirudin, a peptide derived from leech salivary glands, ameliorates diabetic kidney disease (DKD) using db/db mice and in vitro macrophage models. The findings revealed that hirudin reduces SOD2 β-hydroxybutyrylation, which subsequently lowers reactive oxygen species production and suppresses NLRP3 inflammasome activation, ultimately improving kidney parameters. This expands the known therapeutic domain of leech-derived hirudin beyond anticoagulation into potentially novel anti-inflammatory and renoprotective applications. However, the research remains entirely preclinical, relying on animal and cell culture models, and offers no data on clinical human efficacy or direct hirudotherapy dosing.

Citation

Reference (Vancouver style)

Li Y, Wang M, Wu X, Chen J, Peng X, Gan Y, et al. Hirudin ameliorates kidney injury in DKD mice by decreasing SOD2 β-hydroxybutyrylation mediated ROS level and NLRP3 inflammasome formation. FASEB J. 2026;40(2):e71433. doi:10.1096/fj.202502662R. PMID: 41546551

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.